Koichiro Yoneyama

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants.

A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants.

Journal: Journal of thrombosis and haemostasis : JTH
Published: February 14, 2025

Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy.

Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy.

Journal: Thrombosis and haemostasis
Published: August 12, 2024

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan.

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan.

Journal: TH open : companion journal to thrombosis and haemostasis
Published: August 30, 2023

Clinical pharmacology of emicizumab for the treatment of hemophilia A.

Clinical pharmacology of emicizumab for the treatment of hemophilia A.

Journal: Expert review of clinical pharmacology
Published: August 02, 2023

Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.

Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 09, 2022

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.

Journal: Journal of thrombosis and haemostasis : JTH
Published: June 09, 2022

Low immunogenicity of emicizumab in persons with haemophilia A.

Low immunogenicity of emicizumab in persons with haemophilia A.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 11, 2021

A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.

A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.

Journal: Journal of clinical pharmacology
Published: June 02, 2021

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: May 13, 2019

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.

Journal: Clinical pharmacology in drug development
Published: June 14, 2018

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Journal: Clinical pharmacokinetics
Published: December 08, 2017

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.

Journal: Blood advances
Published: March 13, 2017
Showing 1-12 of 15

Last Updated: 09/26/2026